Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

LCZ696 in Advanced LV Hypertrophy and HFpEF

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03928158
Recruitment Status : Recruiting
First Posted : April 26, 2019
Last Update Posted : June 18, 2019
Sponsor:
Collaborator:
Ministry of Health of Russian Federation
Information provided by (Responsible Party):
Nursiyat Ibragimova, National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

Brief Summary:
Patients with advanced LVH and HFpEF will be randomly assigned in open-label fashion to receive LCZ696 titrated to 200 mg twice daily or enalapril titrated to 20 mg twice daily, and will be treated for 24 weeks.

Condition or disease Intervention/treatment Phase
Heart Failure Essential Hypertension Drug: LCZ 696 Drug: Enalapril Phase 2

Detailed Description:
Heart failure with preserved ejection fraction (HFpEF) has a significant morbidity and mortality, and therapies that have proven effective in HF with reduced EF have not been shown to improve long-term prognosis in HFpEF. Inhibition of circulating neprilysin could augment deficient NP-receptor GC signaling and therefore be beneficial in HFpEF, as suggested by the decrease in NP following administration of valsartan/sacubitril in the phase 2 (PARAMOUNT study). Use of valsartan/sacubitril is currently being tested in the multicenter PARAGON-HF trial with HFpEF patients. The investigators suppose the best candidates for LCZ696 therapy will be patients with HFpEF and advanced concentric LV hypertrophy and obesity, i.e. having the lowest BNP bioavailability.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Sacubitril/Valsartan (LCZ696) in Patients With Advanced Hypertensive Left Ventricular Hypertrophy and Heart Failure With Preserved Ejection Fraction: Clinical, Haemodynamic and Neurohumoral Effects (a Phase 2, Randomized, Single-center, Parallel Group Study)
Actual Study Start Date : May 31, 2019
Estimated Primary Completion Date : August 2020
Estimated Study Completion Date : November 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arm Intervention/treatment
Experimental: LCZ 696
Initial dose - 50 mg twice daily, up-titration to 200 mg twice daily. Patients will also receive standard therapy for heart failure (β-blockers, diuretics, MRAs)
Drug: LCZ 696
100 mg tablet

Active Comparator: Enalapril
Initial dose - 2.5 mg twice daily, up-titration to 10 mg twice daily. Patients also will receive standard therapy for heart failure (β-blockers, diuretics, MRAs)
Drug: Enalapril
5 mg tablet




Primary Outcome Measures :
  1. Change in 6-minute walking distance (6MWD) [ Time Frame: 24 weeks ]
    Difference in distance walked during 6-minute walking test (6MWT) between 24 weeks after baseline and at baseline


Secondary Outcome Measures :
  1. Change in exercise time during diastolic stress-test (DST) [ Time Frame: 24 weeks ]
    Difference in exercise time during DST between 24 weeks after baseline and at baseline

  2. Change in left atrial volume index (LAVI) [ Time Frame: 24 weeks ]
    Difference in LAVI assessed by echocardiography between 24 weeks after baseline and at baseline

  3. Change in average E/e' ratio [ Time Frame: 24 weeks ]
    Difference in E/e' ratio assessed by echocardiography both at rest and at peak exercise during diastolic stress test (DST) between 24 weeks after baseline and at baseline

  4. Change estimated pulmonary artery systolic pressure (PASP) [ Time Frame: 24 weeks ]
    Difference in PASP assessed by echocardiography at peak exercise both at rest and at peak exercise during diastolic stress test (DST) between 24 weeks after baseline and at baseline

  5. Change in left ventricular mass index (LVMI) [ Time Frame: 24 weeks ]
    Difference in LVMI assessed by echocardiography between 24 weeks after baseline and at baseline

  6. Change of New York Heart Association (NYHA) functional classification [ Time Frame: 24 weeks ]
    Difference in NYHA class between 24 weeks after baseline and at baseline

  7. Change in Minnesota Living With Heart Failure Questionnaire (MLHFQ) score [ Time Frame: 24 weeks ]
    Difference in MLHFQ score between 24 weeks after baseline and at baseline. The questionnaire is comprised of 21 important physical, emotional and socioeconomic ways heart failure can adversely affect a patient's life. After receiving brief standardized instructions, the patient marks a 0 (zero) to 5 scale to indicate how much each itemized adverse of heart failure has prevented the patient from living as he or she wanted to live during the past 4 weeks. The questionnaire is simply scored by summation of all 21 responses. Score ranges from 0 (best quality of life) to 105 (worst quality of life).

  8. Change in N-terminal pro b-type natriuretic peptide (NT-proBNP) [ Time Frame: 24 weeks ]
    Difference in NT-proBNP plasma levels between 24 weeks after baseline and at baseline

  9. Change in high-sensitivity C-reactive protein (hsCRP) [ Time Frame: 24 weeks ]
    Difference in hsCRP plasma levels between 24 weeks after baseline and at baseline

  10. Change in carboxyterminal propeptide of type I collagen (PICP) [ Time Frame: 24 weeks ]
    DIfference in PICP plasma levels between 24 weeks after baseline and at baseline

  11. Change in carboxyterminal telopeptide of type I collagen (CITP) [ Time Frame: 24 weeks ]
    Difference in CITP plasma levels between 24 weeks after baseline and at baseline

  12. Change in N-Propeptide Of Type III Procollagen (PIIINP) [ Time Frame: 24 weeks ]
    Difference in PIIINP plasma levels between 24 weeks after baseline and at baseline

  13. Change in Growth/differentiation factor 15 (GDF-15) [ Time Frame: 24 weeks ]
    Difference in GDF-15 plasma levels between 24 weeks after baseline and at baseline

  14. Change in sST2 [ Time Frame: 24 weeks ]
    Difference in sST2 plasma levels between 24 weeks after baseline and at baseline

  15. Change in Galectin-3 [ Time Frame: 24 weeks ]
    Difference in Galectin-3 plasma levels between 24 weeks after baseline and at baseline

  16. Change in monocyte chemoattractant-1 (MCP-1) [ Time Frame: 24 weeks ]
    DIfference in MCP-1 plasma levels between 24 weeks after baseline and at baseline



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Moderate/severe hypertensive left ventricular (LV) hypertrophy (LVMi ≥109 g/m² in women and ≥132 g/m² in men);
  2. New York Heart Association (NYHA) class II-III heart failure;
  3. Left ventricular ejection fraction > 50%;
  4. Increased LV filling pressures assessed at rest or at peak exercise by echocardiography
  5. Body mass index (BMI) > 30 kg/m²
  6. Signed and data informed consent

Exclusion Criteria:

  1. Age ≤ 18 years;
  2. Evidence of myocardial ischemia during stress echocardiography;
  3. Chronic atrial flutter or atrial fibrillation;
  4. Alternative cause of left ventricular hypertrophy and impaired diastolic function (hypertrophic/restictive cardiomyopathy, aortic stenosis, constrictive pericarditis and etc.);
  5. NYHA classification I or decompensated heart failure at screening;
  6. Systolic blood pressure < 110 mmHg or > 180 mmHg;
  7. Diastolic blood pressure < 40 mmHg or > 100 mmHg;
  8. Anemia (Hb < 100 g/l);
  9. Significant left sided structural valve disease;
  10. Secondary hypertension;
  11. Dyspnea due to non-cardiac causes such as pulmonary disease, anemia, severe obesity, primary valvular, or myocardial diseases;
  12. Myocardial infarction or myocardial revascularization within the last 3 months of screening;
  13. Stroke or TIA within the last 3 months of screening;
  14. Autoimmunic and oncological diseases;
  15. Impaired renal function, defined as eGFR < 30 ml/min/1.73 m²;
  16. Impaired liver function;
  17. Potassium concentration >5.2 mmol/L.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03928158


Contacts
Layout table for location contacts
Contact: Artem Ovchinnikov, MD, PhD +74954146612 artcardio@mail.ru

Locations
Layout table for location information
Russian Federation
National Medical Research Center for Cardiology Recruiting
Moscow, Russian Federation, 121552
Contact: Nursiyat Ibragimova, MD       nursik0205@gmail.com   
Principal Investigator: Nursiyat Ibragimova, MD         
Sponsors and Collaborators
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Ministry of Health of Russian Federation

Layout table for additonal information
Responsible Party: Nursiyat Ibragimova, principal investigator, MD, National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
ClinicalTrials.gov Identifier: NCT03928158     History of Changes
Other Study ID Numbers: AAAA-A18-118022290061-2
First Posted: April 26, 2019    Key Record Dates
Last Update Posted: June 18, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Nursiyat Ibragimova, National Medical Research Center for Cardiology, Ministry of Health of Russian Federation:
left ventricular hypertrophy
diastolic dysfunction
LCZ696
HFpEF
HF
LV filling pressures

Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Essential Hypertension
Hypertrophy, Left Ventricular
Hypertrophy
Hypertension
Vascular Diseases
Cardiovascular Diseases
Heart Diseases
Pathological Conditions, Anatomical
Cardiomegaly
Enalapril
Enalaprilat
LCZ 696
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents
Angiotensin Receptor Antagonists